Smruthi Suryaprakash’s Post

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions! https://lnkd.in/dN3yhYTs

ADC landscape in Nature Reviews Drug Discovery https://lnkd.in/dyM5fDv5

Did you miss our recent webinar on "Efficiently Driving Protein-based #NMR Fragment Screening and Lead Discovery" ? Dr. Andrew “Dru” Namanja, Principal Research Scientist at AbbVie, explored the potency ranking methods involving both qualitative single-point ligand concentration (Q Score) and quantitative binding affinity (KD), and how the combined utility can be used successfully to drive a Fragment-Based Drug Discovery (#FBDD) campaign. If you missed any part of it, no worries! You can catch the recorded session here: https://lnkd.in/d9RfpXfs #dataautomation #FragmentBasedDrugDiscovery #Mnova #Mestrelab

When it comes to powering advanced in vitro models with iPSCs, quality and consistency are key. So we've produced this infographic to show you how we're achieving excellent quality, consistency, and operational excellence at scale from our world-class production facility in Roslin. It's clear from our market research that the industry values iPSCs: 87% see them as a valuable tool for biopharma, and 75% are increasing their investment into iPSCs this year. But to fulfill the transformative potential of iPSCs for drug discovery, we must prioritize consistency and quality of cells. In fact, consistency was the number 1 reported priority from our market research, particularly at bulk quantities. Over the 10+ years we've been working in this industry, we've developed the operational and technical expertise to deliver high-quality iPSCs at scale, with excellent consistency even at bulk quantities. That's why we're now in the position to collaborate with biopharma groups on complex in vitro models, to accelerate and de-risk drug discovery. Click to download the infographic, and visit our website to find out more. Where does consistency rank on your list of priorities for iPSC suppliers? #iPSCs #StemCells #DrugDiscovery #NeurodegenerativeDisease #QualityControl

Join us for a webinar with Dr. Andrew "Dru" Namanja from AbbVie as he explores potency ranking methods for Fragment-Based Drug Discovery #FBDD. Register here 👉 https://bit.ly/3rNnUpl 👈 Discover how these methods can be used successfully to drive a Fragment-Based Drug Discovery (#FBDD) campaign. Don't forget to register for this insightful session on October 24th! #drugdiscovery #NMR #MnovaRocks #NMRchat SciY

#ADC research is rapidly evolving, but also presents challenges for innovators and drug developers seeking to understand the complex and competitive #IP landscape. Check out our on-demand webinar to learn more: https://ow.ly/RB5P50QexhQ

Optimized Molecules for Optimized Profiles: An AI-Driven Platform for Small Molecule Drug Discovery with Fred Manby from Iambic Therapeutics. Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need. Our platform enables us to widely explore chemical space, while also sampling a wide range of target product profiles. We have demonstrated our platform on initial programs, with our first scheduled for clinical entry just two years after launch. https://lnkd.in/eDBzUurr Save $150 with Discount code SPK150. #drugdiscoverychemistry

Don't miss Kim Frederix at today's congress of European Drug Discovery Innovation & Outsourcing Programme organized by Drug Discovery Innovation Programme (DDIP). Schedule a meeting now to discover how InnoSer can help you achieve breakthroughs on your preclinical drug discovery path! InnoSer is active in #DrugDevelopment pipelines, spanning from the early target validation until the late preclinical research phase. Learn more about how you can benefit from our capabilities here: https://lnkd.in/eciRBYbq #DDIP #DDIPEU

Considering starting your next #drugdiscovery program? Partnering with a trusted ally to minimize risks and propel candidates with the best profile is key. Tap into our expertise and proven preclinical track record. https://okt.to/14G85T

𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗟𝗮𝗯𝗜𝗡𝗔𝗥 𝗕𝗿𝗲𝗮𝗸 𝘆𝗲𝘁? Time is running out – this event is happening on Thursday! 📅 Date: May 16th, 2024 🕓 Time: 16:00 CEST Reserve your seat for an enlightening first session with Dr. Matthias Gossmann at the LabINAR BREAK, hosted by innoVitro. Discover the transformative strategies in drug discovery using iPSC-cellular models during the webinar “Transforming Drug Discovery: Accelerating Regulatory Acceptance by Integrating Throughput into Microphysiological Systems". What can you expect? ▪️ Case studies highlighting the successful application of these models ▪️ Insights on utilizing cell-based platforms for efficient preclinical drug screening ▪️ An engaging & interactive Q&A sessions with field experts. Will we see you at the webinar? Register today to reserve your spot. Secure your registration: https://ow.ly/JTE950RuB0I #InnovativeDrugDiscovery #Webinar #HighThroughput #iPSCModels #Preclinical #PharmaceuticalDevelopment